BiomX publishes Phase 1b/2a BX004 data in Nature Communications; shows 500-fold bacterial reduction

BiomX Inc.

BX004 achieved 2.7 log10 (~500-fold) greater bacterial reduction vs placebo in CF patients with chronic P. aeruginosa infections.
No bacterial resistance to BX004 emerged during the trial, addressing a key limitation of antibiotics.
Phase 2b trial of BX004 initiated; topline results expected Q1 2026.
BX004 was safe and well-tolerated with no treatment-related safety events across all patients and dose levels.
Therapeutic phages were detected at infection site up to one week after end of therapy.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.